Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion type Assertion NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_head.
- NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_provenance.
- NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion evidence source_evidence_literature NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_provenance.
- NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion SIO_000772 21942328 NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_provenance.
- NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion wasDerivedFrom befree-20140225 NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_provenance.
- NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion wasGeneratedBy ECO_0000203 NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_provenance.